Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo

Juan Chen, Ian R. Corbin, Hui Li, Weiguo Cao, Jerry D. Glickson, Gang Zheng

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

LDL particles are high-capacity nanocarriers with precisely controlled size and are naturally biocompatible, biodegradable, and nonimmunogenic. However, their utilities as drug carriers are limited by the narrow purview of LDL receptor-positive tumors. Here, we synthsized a ligand-conjugated, NIR-labeled LDL that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.

Original languageEnglish (US)
Pages (from-to)5798-5799
Number of pages2
JournalJournal of the American Chemical Society
Volume129
Issue number18
DOIs
StatePublished - May 9 2007

Fingerprint

Lipoproteins
Optical Imaging
LDL Lipoproteins
Nanoparticles
Tumors
Demonstrations
Ligands
Imaging techniques
LDL Receptors
Neoplasms
Drug Carriers
oxidized low density lipoprotein
Therapeutics

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. / Chen, Juan; Corbin, Ian R.; Li, Hui; Cao, Weiguo; Glickson, Jerry D.; Zheng, Gang.

In: Journal of the American Chemical Society, Vol. 129, No. 18, 09.05.2007, p. 5798-5799.

Research output: Contribution to journalArticle

Chen, Juan ; Corbin, Ian R. ; Li, Hui ; Cao, Weiguo ; Glickson, Jerry D. ; Zheng, Gang. / Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. In: Journal of the American Chemical Society. 2007 ; Vol. 129, No. 18. pp. 5798-5799.
@article{413458d50da04bef8dc07dd2e1d33022,
title = "Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo",
abstract = "LDL particles are high-capacity nanocarriers with precisely controlled size and are naturally biocompatible, biodegradable, and nonimmunogenic. However, their utilities as drug carriers are limited by the narrow purview of LDL receptor-positive tumors. Here, we synthsized a ligand-conjugated, NIR-labeled LDL that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.",
author = "Juan Chen and Corbin, {Ian R.} and Hui Li and Weiguo Cao and Glickson, {Jerry D.} and Gang Zheng",
year = "2007",
month = "5",
day = "9",
doi = "10.1021/ja069336k",
language = "English (US)",
volume = "129",
pages = "5798--5799",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo

AU - Chen, Juan

AU - Corbin, Ian R.

AU - Li, Hui

AU - Cao, Weiguo

AU - Glickson, Jerry D.

AU - Zheng, Gang

PY - 2007/5/9

Y1 - 2007/5/9

N2 - LDL particles are high-capacity nanocarriers with precisely controlled size and are naturally biocompatible, biodegradable, and nonimmunogenic. However, their utilities as drug carriers are limited by the narrow purview of LDL receptor-positive tumors. Here, we synthsized a ligand-conjugated, NIR-labeled LDL that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.

AB - LDL particles are high-capacity nanocarriers with precisely controlled size and are naturally biocompatible, biodegradable, and nonimmunogenic. However, their utilities as drug carriers are limited by the narrow purview of LDL receptor-positive tumors. Here, we synthsized a ligand-conjugated, NIR-labeled LDL that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.

UR - http://www.scopus.com/inward/record.url?scp=34248597761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248597761&partnerID=8YFLogxK

U2 - 10.1021/ja069336k

DO - 10.1021/ja069336k

M3 - Article

C2 - 17428054

AN - SCOPUS:34248597761

VL - 129

SP - 5798

EP - 5799

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 18

ER -